PL2193793T3 - Inhibitor śmierci komórek nerwowych - Google Patents

Inhibitor śmierci komórek nerwowych

Info

Publication number
PL2193793T3
PL2193793T3 PL08836702T PL08836702T PL2193793T3 PL 2193793 T3 PL2193793 T3 PL 2193793T3 PL 08836702 T PL08836702 T PL 08836702T PL 08836702 T PL08836702 T PL 08836702T PL 2193793 T3 PL2193793 T3 PL 2193793T3
Authority
PL
Poland
Prior art keywords
cell death
nerve cell
death inhibitor
inhibitor
nerve
Prior art date
Application number
PL08836702T
Other languages
English (en)
Inventor
Fumiyasu Sato
Yasunobu Yoshinaka
Taro Aoki
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of PL2193793T3 publication Critical patent/PL2193793T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL08836702T 2007-10-03 2008-10-02 Inhibitor śmierci komórek nerwowych PL2193793T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007259682 2007-10-03
EP08836702A EP2193793B1 (en) 2007-10-03 2008-10-02 Nerve cell death inhibitor
PCT/JP2008/002768 WO2009044547A1 (ja) 2007-10-03 2008-10-02 神経細胞死抑制剤

Publications (1)

Publication Number Publication Date
PL2193793T3 true PL2193793T3 (pl) 2012-12-31

Family

ID=40525979

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08836702T PL2193793T3 (pl) 2007-10-03 2008-10-02 Inhibitor śmierci komórek nerwowych

Country Status (13)

Country Link
US (1) US7973053B2 (pl)
EP (1) EP2193793B1 (pl)
JP (1) JP5399909B2 (pl)
KR (1) KR101503782B1 (pl)
CN (1) CN101815517A (pl)
CA (1) CA2701397C (pl)
CY (1) CY1113364T1 (pl)
DK (1) DK2193793T3 (pl)
ES (1) ES2389392T3 (pl)
PL (1) PL2193793T3 (pl)
PT (1) PT2193793E (pl)
TW (1) TWI432195B (pl)
WO (1) WO2009044547A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018000228A1 (zh) 2016-06-29 2018-01-04 北京小米移动软件有限公司 数据传输方法、装置和终端

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
JP3992806B2 (ja) 1997-12-12 2007-10-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 ドネペジル中間体の製造法
JP4022332B2 (ja) 1998-01-16 2007-12-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 ドネペジル誘導体の製造法およびその中間体
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
JP2003523948A (ja) 1999-11-04 2003-08-12 アンドルクス コーポレーション アミロイドβ前駆体障害の治療法
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
CA2437480A1 (en) 2001-02-05 2002-08-15 Andrx Corporation Method of treating amyloid .beta. precursor disorder
MXPA04009535A (es) 2002-04-02 2005-01-25 Janssen Pharmaceutica Nv Terapia con estatina para mejorar el mantenimiento cognoscitivo.
AU2004222529A1 (en) * 2003-03-19 2004-09-30 Ares Trading S.A. INF-beta alone or in combination with other medicaments for treating Alzheimer's disease and demens disorders
ATE535614T1 (de) 2003-12-30 2011-12-15 Kowa Co Screening-verfahren fuer gamma-sekretase- inhibitoren
CN1960781A (zh) * 2004-04-14 2007-05-09 沃尼尔·朗伯有限责任公司 治疗阿尔茨海默氏病的治疗组合
KR101436644B1 (ko) 2006-01-31 2014-09-01 코와 가부시키가이샤 당뇨병 치료제

Also Published As

Publication number Publication date
KR20100072227A (ko) 2010-06-30
EP2193793A4 (en) 2011-02-09
KR101503782B1 (ko) 2015-03-18
JPWO2009044547A1 (ja) 2011-02-03
CY1113364T1 (el) 2016-06-22
CN101815517A (zh) 2010-08-25
DK2193793T3 (da) 2012-08-20
TWI432195B (zh) 2014-04-01
PT2193793E (pt) 2012-09-28
ES2389392T3 (es) 2012-10-25
EP2193793A1 (en) 2010-06-09
CA2701397A1 (en) 2009-04-09
JP5399909B2 (ja) 2014-01-29
WO2009044547A1 (ja) 2009-04-09
TW200918059A (en) 2009-05-01
US20100173938A1 (en) 2010-07-08
US7973053B2 (en) 2011-07-05
EP2193793B1 (en) 2012-08-01
CA2701397C (en) 2015-11-03

Similar Documents

Publication Publication Date Title
IL221851A0 (en) Targeted cell death
GB0720484D0 (en) Cells
PL2361922T3 (pl) Produkty pośrednie do wytwarzania inhibitorów nukleozydowych HCV
GB0714485D0 (en) Stimulator
IL196134A0 (en) Cell death inducer
GB2454508B (en) Electrode structures
ZA201100797B (en) Electrodepositable composition
GB0700361D0 (en) Pack
TWI372862B (en) Reference electrode
ZA200908588B (en) Pack
GB0720292D0 (en) Equation solving
GB0610596D0 (en) Electrode
PL2193793T3 (pl) Inhibitor śmierci komórek nerwowych
EP2191261A4 (en) ELECTRODE
GB0714941D0 (en) Inhibitors
EP2253636A4 (en) INHIBITOR OF NEURONAL CELL DEATH
GB0605548D0 (en) Cell inhibitor
GB0713152D0 (en) Phosphodlesterase inhibitors
GB0720364D0 (en) Inhibitor
GB0700936D0 (en) Cells
GB0708483D0 (en) Electrodes
ZA200805575B (en) Land electrode
PL380136A1 (pl) Ogniwo fotowoltaiczne
GB0704589D0 (en) Novel inhibitors
GB0707632D0 (en) Novel inhibitors